by John Conrad | Mar 9, 2020 | COVID, Member News
AbbVie (NYSE:ABBV) today confirmed the company’s activities in the fight to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Kaletra/Aluvia (lopinavir/ritonavir) to determine its efficacy in the treatment...
by John Conrad | Feb 27, 2020 | COVID
As one of the first pharmaceutical companies to respond to the emerging novel coronavirus (COVID-19) crisis, in late January, AbbVie donated a supply of Kaletra/Aluvia (lopinavir/ritonavir) to the Chinese health authorities for use as an experimental treatment option....
